Ventum Cap Mkts Decreases Earnings Estimates for Cresco Labs

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Equities researchers at Ventum Cap Mkts reduced their FY2025 EPS estimates for Cresco Labs in a research report issued on Wednesday, March 12th. Ventum Cap Mkts analyst A. Semple now forecasts that the company will post earnings of ($0.09) per share for the year, down from their prior forecast of ($0.08). The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share.

CRLBF has been the topic of several other reports. Cormark upgraded shares of Cresco Labs from a "hold" rating to a "moderate buy" rating in a research report on Monday. Atb Cap Markets downgraded shares of Cresco Labs from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 9th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $3.00.

Cresco Labs Stock Performance

Shares of Cresco Labs stock traded up $0.01 on Monday, reaching $0.72. 2,218,801 shares of the stock were exchanged, compared to its average volume of 621,663. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80. The business has a fifty day moving average price of $0.87 and a two-hundred day moving average price of $1.18. Cresco Labs has a 1-year low of $0.70 and a 1-year high of $2.60. The firm has a market capitalization of $349.02 million, a PE ratio of -3.58 and a beta of 1.79.

Remove Ads

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last announced its earnings results on Friday, March 14th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%. The business had revenue of $176.00 million during the quarter, compared to analysts' expectations of $172.10 million.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.